ACTG254--MICRONIZED ATOVAQUONE & AT/AZ AS COMPARED TO TM/ SMX

ACTG254--微粉化阿托伐醌

• 批准号: 6264756
• 负责人: RICHARD RUTSTEIN
• 金额: $ 0.06万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264756
• 关键词: AIDS therapy; HIV infections; antibacterial agents; atovaquone; azithromycin; chemoprevention; clinical research; clinical trial phase I; combination chemotherapy; drug interactions; human data; human subject; human therapy evaluation; infant human (0-1 year); pediatric AIDS; pharmacokinetics; preschool child (1-5); sulfamethoxazole; trimethoprim

ACTG 254 is a comparative study of two drug combinations (atovaquone/azithromycin vs. trimethoprim/sulfamethoxazole) for the prevention of serious bacterial infections in HIV-infected children. The lower age limit for enrollment into this study was lowered to 3 months (from 2 years) in March 1997. On February 12, 1999, this study will close to accrual of patients older than 19 months of age. Treatment and data collection continue in all age cohorts. Preliminary data from a pharmacokinetic substudy suggest that there is no pharmacokinetic interaction between atovaquone and azithromycin. No preliminary efficacy data are available from this study.

ACTG 254是两种药物组合（阿托伐醌/阿奇霉素与甲氧苄啶/磺胺甲恶唑）预防艾滋病毒感染儿童严重细菌感染的比较研究。 1997年3月，本研究入组的年龄下限降至3个月（从2岁）。 1999年2月12日，本研究将结束年龄大于19个月的患者入组。 在所有年龄组中继续进行治疗和数据收集。 药代动力学亚组研究的初步数据表明，阿托伐醌和阿奇霉素之间没有药代动力学相互作用。 本研究未提供初步疗效数据。